Company classified this as operating lease. This lease does not contain renewal. The Company's leases do not include termination options for either party to the lease or restrictive financial or other covenants. Payments due under the lease contracts include fixed payments. Leases are classified as operating leases at the lease commencement date. Lease expense on operating leases and short-term leases is recognized on a straight-line basis over the lease term. Right-of-use assets payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of the lease payments over the lease term. The Company uses its incremental not known. The Company's incremental borrowing rate is 4%. Amount reported in the balance sheet as at December 31, 2025 was as follows: Other information related to leases as at December 31, 2025 was as follows: https://www.sec.gov/Archives/edgar/data/1865759/000147793226000746/pharmaceutical_s1.htm